

Sustainability Policy

version 1.0

Effective Period	Effective upon approval by the Executive Board; reviewed at least once a year
Version	1.0
Date	September 29, 2026
Prepared/modified by	Prof. Dr. Gökmen Zararsız
Approved by	Executive Board, Hematainer Biotechnology and Health Products Inc. Kayseri, Türkiye
Reasons for modification	Initial version

1. Introduction

Human health, environmental impacts and the principles of responsible business conduct are jointly observed in Hematainer's volumetric microsampling technologies, metabolomic and lipidomic analytical services, bioinformatics work, and OmegaTree research and development activities. This policy establishes the corporate framework for the growing company to base its decisions on measurable data and to reduce its adverse impacts.

2. Scope and Responsibility

The policy covers the design, procurement, production and life cycle of the MAS-10 and MAS-30 products, laboratory analyses, data analytics, logistics and office activities, as well as employees, interns and relevant suppliers. Resources and priorities are set by the Executive Board; implementation is monitored by process owners; employees report risks and improvement suggestions related to their own duties.

3. Health, Safety and Scientific Reliability

- ✓ The safety of participants, users and employees is safeguarded in microsampling and analytical processes; biological samples, chemicals and sharps are managed through defined procedures.
- ✓ Claims regarding product performance, method validity, intended use and the interpretation of results are based on evidence and relevant regulatory requirements. Applications at the research stage are clearly distinguished from established services.
- ✓ Scientific integrity, participant rights and ethics approval requirements are observed in all studies; an inclusive working environment aligned with the Gender Equality Plan is supported.

4. Environmental Impact and Resource Use

- ✓ Material use, durability, safe use and waste generation are evaluated together in product and packaging design; the reduction of unnecessary material use is targeted without compromising quality and biosafety conditions.
- ✓ Hazardous chemical, infectious and sharps waste is segregated at source in the laboratories; storage, transport and disposal processes are monitored in line with applicable legislation. Biological samples and test consumables are not directed to household waste or inappropriately to recycling.
- ✓ Energy and water consumption, equipment use, solvents and consumables, shipment and packaging data are monitored at an appropriate scale; feasible reduction opportunities are reviewed annually.
- ✓ The potential of MAS® technology for low-volume sampling and, under certain conditions, simplified transport is evaluated. Claims of environmental benefit are not generalised without verification through comparative data on the analyte, protocol, packaging, shipping and disposal conditions.

5. People and Supply Chain

- ✓ Principles of equal opportunity, a safe working environment, respectful communication and the prevention of discrimination are applied in recruitment, development and working conditions.
- ✓ Quality, traceability, occupational health and safety, business ethics and environmental compliance are taken into account in supplier selection; appropriate records and commitments are requested from critical suppliers.
- ✓ Responsibilities for intellectual property, confidentiality, data protection and research ethics are defined in writing in university, clinical and industrial partnerships.

6. Data, Artificial Intelligence and Transparency

When developing data-driven solutions, including OmegaTree, personal and health data are processed only to the extent required by the purpose, access is restricted according to authorisation, and the scientific limitations of the results are disclosed. The validity of algorithms, their performance across different groups and human oversight are evaluated at the appropriate stages of development. No unsupported diagnostic or therapeutic claims are made to users.

7. Monitoring and Improvement

Indicators such as energy and water consumption, quantities of hazardous and non-hazardous waste, consumable and packaging use per product where appropriate, occupational health and safety incidents, training activities and supplier non-conformities are reviewed by management at least once a year. The first measurement period is taken as the baseline; time-bound targets are set as data become available. Progress and significant changes are communicated with verifiable information.

This policy is updated whenever legislation, the product portfolio, the service model or stakeholder expectations change. Contact: info@hematainer.com

Approved on: September 2026

This document is signed by all co-founders of Hematainer Biotechnology and Health Products Inc.

Prof. Dr. Mehmet Doğan



Prof. Dr. Halef Okan Doğan



Prof. Dr. Gökmen Zararsız

